Dr. Beth Seidenberg focuses on life science investing and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining Kleiner Perkins Caufield & Byers in 2005, Beth has incubated five companies and was the founding CEO of two: Arresto (sold to Gilead in 2011), focused on antibody therapeutics for cancer and fibrosis; 3-V Biosciences, focused on therapeutics for infectious diseases; Auxogyn, focused on device and diagnostics for in-vitro fertilization; Epizyme, focused on therapeutics based on epigenetic targets; and iPierian, focused on drug discovery for neurodegenerative disorders using induced pluripotent stem cells (iPS). Beth serves on the board of directors of 3-V Biosciences, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO.
Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.
Beth is the chairman and founder of NVCA-MedIC coalition, which focuses on FDA reform, and she is an advocate for fast and safe access to innovative products. She also serves on the foundation board at the Gladstone Institute and the Stanford Coulter Foundation oversight committee. Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
